WEE1 and acute myeloid leukemia: In combination with WEE1 inhibition, impaired activity of the cell cycle checkpoint kinase and premature mitotic entry lead to an increase in DNA damage and apoptosis, making this combination a promising target for the treatment of acute myeloid leukemia (AML) [150].